ID: ALA94715

Max Phase: Preclinical

Molecular Formula: C12H14N2O5S

Molecular Weight: 298.32

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC#CCOc1ccc(S(=O)(=O)NCC(=O)NO)cc1

Standard InChI:  InChI=1S/C12H14N2O5S/c1-2-3-8-19-10-4-6-11(7-5-10)20(17,18)13-9-12(15)14-16/h4-7,13,16H,8-9H2,1H3,(H,14,15)

Standard InChI Key:  XRLMAIWPTHLVKY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 298.32

Molecular Weight (Monoisotopic): 298.0623

AlogP: -0.13

#Rotatable Bonds: 6

Polar Surface Area: 104.73

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.74

CX Basic pKa:

CX LogP: 0.38

CX LogD: 0.36

Aromatic Rings: 1

Heavy Atoms: 20

QED Weighted: 0.39

Np Likeness Score: -1.09

References

1. Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustian S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS..  (2003)  Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.,  13  (16): [PMID:12873518] [10.1016/s0960-894x(03)00514-6]

2. Verma RP, Hansch C..  (2007)  Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.,  15  (6): [PMID:17275314] [10.1016/j.bmc.2007.01.011]

3. Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A..  (2013)  Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.,  56  (20): [PMID:24044434] [10.1021/jm4011753]

Source

Source(1):

• Scientific Literature